Welcome to LookChem.com Sign In|Join Free

CAS

  • or

65807-02-5

Post Buying Request

65807-02-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

65807-02-5 Usage

Description

Goserelin is an analog of luteinizing hormone-releasing hormone (LHRH) useful in the treatment of malignancies responsive to hormonal manipulation. Administered parenterally in a biodegradable depot, goserelin is reportedly as effective as orchidectomy and oophorectomy in patients with advanced prostate carcinoma and pre-menopausal breast cancer.

Chemical Properties

White or almost white powder.

Uses

Different sources of media describe the Uses of 65807-02-5 differently. You can refer to the following data:
1. Goserelin USP (Zoladex) is used to treat Prostatic carcinoma.
2. Labelled Goserelin (G767500). Synthetic peptide agonist analog of LH-RH. Antineoplastic (hormonal).
3. Labeled Goserelin, intended for use as an internal standard for the quantification of Goserelin by GC- or LC-mass spectrometry.

Manufacturing Process

(a) Solid Phase Preparation of NonapeptideThe solid phase synthesis was carried out in automatic mode on an Applied Biosystems 430A Peptide Synthesizer using Boc-Pro-OBzl-polystyrene resin 1% cross-linked with divinylbenzene (Peninsula Laboratories), 1.25 g, 0.38 meq/g though nominally 0.7 meq/g). The following protected amino acids were converted to benzotriazolyl esters by reaction with HOBt (1- hydroxybenzotriasole) and DIPC (di-isopropylcarbodiimide) in DMF immediately before use. The protected amino acids were coupled in the following sequence: Boc-Arg(HCl)-OH; Boc-Leu-OH; Fmoc-D-Ser(But)-OH; Fmoc-Tyr(BrZ)-OH; Fmoc-Ser-OH; Fmoc-Trp-OH; Fmoc-His(Fmoc)-OH; PyrOH. The sequence of operations for the first two stages (using Boc-protectedamino acids) was: removal of Boc with 45% triflouroacetic acid in dichloromethane;10% DIEA (diethyl amine)/DMF wash; coupling (2 equivalents of protected amino acid HOBt ester); removal of Boc as above. The sequence of operations for the last six stages (using Fmoc-protectedamino acids) was: removal of Fmoc with 20% piperidine/DMF; 0.5 molar HOBt/DMF wash; coupling (1 equivalent of protected amino acid HOBt ester). All coupling reactions except that using Boc-Arg(HCl)-OH were of 1 hour duration; the Boc-Arg(HCl)-OH one was of 2 hours duration. There was thus obtained the nonapeptide-resin (1.7 g; 0.29 mmole peptide per g) with the Tyr still protected by BrZ. (b) Cleavage of Peptide From Resin The peptide resin prepared above was treated with a 20-fold excess of anhydrous hydrazine in DMF (20 ml) at laboratory temperature for 24 hours, and the mixture was filtered and evaporated to dryness. This procedure also removed the BrZ protecting group from the Tyr moeity. The residue was purified by gel filtration on a column (LH 20 Sephadex) using a 20:1 v/v mixture of water and acetic acid as eluant. There was thus obtained Pyr-HisTrp-Ser-Tyr-D-Ser(But)-Leu-Arg(H+)-Pro-NH-NH2. The structure of which was confirmed by amino acid analysis and mass spectroscopy. (c) Preparation of Goserelin A solution of potassium cyanate (11 mg) in water (1.36 ml) was added portionwise during 1 hour to a solution of the above hydrazide (118 mg) in a 20:1 v/v mixture of water and acetic acid (10 ml). The mixture was freezedried and the residue was purified by reverse-phase column chromatography (Dynamax 60 ANG, C18, 1 inch diameter) using a gradient of 10% to 40% by volume of acetonitrile in water containing 0.1% trifluoroacetic acid. There was thus obtained goserelin (100 mg, 25% yield overall), the structure of which was confirmed by mass spectroscopy.

Brand name

Zoladex (Zeneca).

Therapeutic Function

Antineoplastic, Antitumor

Clinical Use

Synthetic decapeptide analogue of LHRH: Treatment of advanced prostate cancer, breast cancer, endometriosis and endometrial thinning and uterine fibroids

Drug interactions

Potentially hazardous interactions with other drugs None known

Metabolism

Metabolised by tissue peptidases and is excreted in urine and bile as unchanged drug and metabolites.

Check Digit Verification of cas no

The CAS Registry Mumber 65807-02-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,5,8,0 and 7 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 65807-02:
(7*6)+(6*5)+(5*8)+(4*0)+(3*7)+(2*0)+(1*2)=135
135 % 10 = 5
So 65807-02-5 is a valid CAS Registry Number.
InChI:InChI=1/C59H84N18O14/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90)/t38-,39-,40-,41-,42-,43-,44-,45+,46-/m0/s1

65807-02-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017

1.Identification

1.1 GHS Product identifier

Product name Goserelin

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:65807-02-5 SDS

65807-02-5Upstream product

65807-02-5Downstream Products

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 65807-02-5